When you have deep vein thrombosis (DVT), a blood clot in a vein deep inside your body, doctors try to keep the clot from getting bigger and stop new clots from forming. One of their top priorities is ...
A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer No significant financial relationships to ...
Clinical guidelines recommend low-molecular-weight heparin for thromboprophylaxis in patients with fractures, but trials of its effectiveness as compared with aspirin are lacking. In this pragmatic, ...
Heparin-induced thrombocytopenia (HIT) is an immune-mediated platelet disorder caused by antibodies that target complexes of platelet factor 4 (PF4) and heparin. HIT has been characterized as a ...
Blood thinners don’t really thin your blood. They just interrupt your body’s natural clotting process. Warfarin and heparin act on different parts of this process. Doctors usually prescribe warfarin ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Heparin-based ...
Scientists at the University of California-San Diego say they have moved one step closer to the ability to make heparin in cultured cells. Heparin is a potent anti-coagulant and the most prescribed ...
The Journal of Cell Biology (JCB) is a not-for-profit publication, edited by scientists, and a leading life sciences journal. The JCB publishes papers on all aspects of cellular structure and function ...
The Ohio biotechnology firm Optimvia Pharmaceuticals says it has developed a cost-effective synthetic method to produce large quantities of heparin, which is used to make a common blood thinner. And ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback